Literature DB >> 16581319

Altered protein profile in chronic myeloid leukemia chronic phase identified by a comparative proteomic study.

Luciana Pizzatti1, Lílian Ayres Sá, Jamison Menezes de Souza, Paulo Mascarello Bisch, Eliana Abdelhay.   

Abstract

Chronic myeloid leukemia is a hematological disorder in which the Ph chromosome is a marker of the disease, detected virtually in all cases. The chimeric transcripts encode a 210-kDa chimeric protein with altered tyrosine kinase activity, responsible for the disease phenotype. In this work, we tried to identify which are the molecular changes common to chronic phase patients, those that represent the chronic phase molecular phenotype. To address this problem we analyzed through a comparative proteomic approach, several CML bone marrow cells protein profile from patients in chronic phase and healthy bone marrow donors. From these results, we identified 31 differentially expressed proteins. Among these proteins, we pointed out c-Myc binding protein 1, 53BP1, Mdm4, OSBP-related protein 3 and Mortalin as putative candidates to BCR-ABL targets in chronic phase. Moreover, we describe for the first time the cytoplasmic protein map from bone marrow cells that helped in the elucidation of the changes we were looking for.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16581319     DOI: 10.1016/j.bbapap.2006.02.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Atypical activation of signaling downstream of inactivated Bcr-Abl mediates chemoresistance in chronic myeloid leukemia.

Authors:  Mythreyi Narasimhan; Vaishnavi Khamkar; Sarika Tilwani; Sorab N Dalal; Dhanlaxmi Shetty; P G Subramanian; Sanjay Gupta; Rukmini Govekar
Journal:  J Cell Commun Signal       Date:  2021-10-01       Impact factor: 5.908

2.  A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line.

Authors:  Stephany Corrêa; Luciana Pizzatti; Bárbara Du Rocher; André Mencalha; Daniela Pinto; Eliana Abdelhay
Journal:  Proteome Sci       Date:  2012-03-30       Impact factor: 2.480

3.  SMR peptide antagonizes mortalin promoted release of extracellular vesicles and affects mortalin protection from complement-dependent cytotoxicity in breast cancer cells and leukemia cells.

Authors:  Ming-Bo Huang; Jennifer Y Wu; James Lillard; Vincent C Bond
Journal:  Oncotarget       Date:  2019-09-10

4.  GRP75-mediated upregulation of HMGA1 stimulates stage I lung adenocarcinoma progression by activating JNK/c-JUN signaling.

Authors:  Guo-Bing Qiao; Ren-Tao Wang; Shu-Nan Wang; Shao-Lin Tao; Qun-You Tan; Hua Jin
Journal:  Thorac Cancer       Date:  2021-03-23       Impact factor: 3.500

5.  Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties.

Authors:  Andrea Prodosmo; Simona Giglio; Sonia Moretti; Francesca Mancini; Flavia Barbi; Nicola Avenia; Giusy Di Conza; Holger J Schünemann; Lorenza Pistola; Vienna Ludovini; Ada Sacchi; Alfredo Pontecorvi; Efisio Puxeddu; Fabiola Moretti
Journal:  J Mol Med (Berl)       Date:  2008-03-12       Impact factor: 4.599

6.  Subcellular proteomic approach for identifying the signaling effectors of protein kinase C-β₂ under high glucose conditions in human umbilical vein endothelial cells.

Authors:  Min Zhang; Fang Sun; Fangfang Chen; Bo Zhou; Yaqian Duan; Hong Su; Xuebo Lin
Journal:  Mol Med Rep       Date:  2015-09-30       Impact factor: 2.952

7.  Targeting GRP75 improves HSP90 inhibitor efficacy by enhancing p53-mediated apoptosis in hepatocellular carcinoma.

Authors:  Weiwei Guo; Lichong Yan; Ling Yang; Xiaoyu Liu; Qiukai E; Peiye Gao; Xiaofei Ye; Wen Liu; Ji Zuo
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

8.  Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.

Authors:  Sheela A Abraham; Lisa E M Hopcroft; Emma Carrick; Mark E Drotar; Karen Dunn; Andrew J K Williamson; Koorosh Korfi; Pablo Baquero; Laura E Park; Mary T Scott; Francesca Pellicano; Andrew Pierce; Mhairi Copland; Craig Nourse; Sean M Grimmond; David Vetrie; Anthony D Whetton; Tessa L Holyoake
Journal:  Nature       Date:  2016-06-08       Impact factor: 49.962

9.  Oncogenic role of mortalin contributes to ovarian tumorigenesis by activating the MAPK-ERK pathway.

Authors:  Yingying Hu; Ling Yang; Yujie Yang; Yanyan Han; Yongbo Wang; Wen Liu; Ji Zuo
Journal:  J Cell Mol Med       Date:  2016-07-04       Impact factor: 5.310

10.  The Zn-finger domain of MdmX suppresses cancer progression by promoting genome stability in p53-mutant cells.

Authors:  Z Matijasevic; A Krzywicka-Racka; G Sluder; J Gallant; S N Jones
Journal:  Oncogenesis       Date:  2016-10-03       Impact factor: 7.485

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.